{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:59:19Z","timestamp":1778853559109,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T00:00:00Z","timestamp":1340236800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2458-12-468","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T18:59:00Z","timestamp":1347303540000},"source":"Crossref","is-referenced-by-count":41,"title":["Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Neela D","family":"Goswami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara Beth","family":"Gadkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Piedrahita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Bissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall Alex","family":"Ahearn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela LM","family":"Blain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truls","family":"\u00d8stbye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi","family":"Saukkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E","family":"Stout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,21]]},"reference":[{"issue":"8","key":"4213_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","volume":"137","author":"RM Jasmer","year":"2002","unstructured":"Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002, 137 (8): 640-647.","journal-title":"Ann Intern Med"},{"issue":"5","key":"4213_CR2","first-page":"551","volume":"14","author":"A Trajman","year":"2010","unstructured":"Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D: Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010, 14 (5): 551-559.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"4213_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh","year":"2010","unstructured":"Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al: Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010, 137 (2): 401-409. 10.1378\/chest.09-0394.","journal-title":"Chest"},{"issue":"11","key":"4213_CR4","first-page":"1235","volume":"12","author":"Y Hirsch-Moverman","year":"2008","unstructured":"Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008, 12 (11): 1235-1254.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"4213_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1086\/647944","volume":"49","author":"PD Ziakas","year":"2009","unstructured":"Ziakas PD, Mylonakis E: 4\u2009months of rifampin compared with 9\u2009months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009, 49 (12): 1883-1889. 10.1086\/647944.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4213_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"F Gordin","year":"2000","unstructured":"Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, et al: Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000, 283 (11): 1445-1450. 10.1001\/jama.283.11.1445.","journal-title":"JAMA"},{"issue":"9105","key":"4213_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","volume":"351","author":"NA Halsey","year":"1998","unstructured":"Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, et al: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998, 351 (9105): 786-792. 10.1016\/S0140-6736(97)06532-X.","journal-title":"Lancet"},{"issue":"31","key":"4213_CR8","first-page":"735","volume":"52","author":"S CfDCaPCAT","year":"2003","unstructured":"CfDCaPCAT S: Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2013United States, 2003. MMWR Morb Mortal Wkly Rep. 2003, 52 (31): 735-739.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"4213_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","volume":"15","author":"P Lobue","year":"2010","unstructured":"Lobue P, Menzies D: Treatment of latent tuberculosis infection: an update. Respirology. 2010, 15 (4): 603-622. 10.1111\/j.1440-1843.2010.01751.x.","journal-title":"Respirology"},{"key":"4213_CR10","volume-title":"The PREVENT TB Study of 3 months of once-weekly rifapentine plus INH vs. 9 months of daily INH for treatment of latent TB infection: first report of results of a multi-center, randomized clinical trial","author":"BA Sterling TR","year":"2010","unstructured":"Sterling TR BA, Shang N, Bliven-Sizemore E, Chaisson RE, Gordin F, Hackman J, Hamilton CD, Horsburgh CR, Kerrigan A, Menzies D, Scott N, Villarino ME, and the Tuberculosis Trials Consortium: The PREVENT TB Study of 3 months of once-weekly rifapentine plus INH vs. 9 months of daily INH for treatment of latent TB infection: first report of results of a multi-center, randomized clinical trial. 2010, In: 41st Union World Conference on Lung Health: November 2010, Berlin, Germany"},{"issue":"4","key":"4213_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","volume":"168","author":"PA LoBue","year":"2003","unstructured":"LoBue PA, Moser KS: Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003, 168 (4): 443-447. 10.1164\/rccm.200303-390OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"4213_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jinf.2006.04.010","volume":"54","author":"AE Parsyan","year":"2007","unstructured":"Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR: Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007, 54 (3): 262-266. 10.1016\/j.jinf.2006.04.010.","journal-title":"J Infect"},{"issue":"5","key":"4213_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1378\/chest.122.5.1609","volume":"122","author":"SJ Shukla","year":"2002","unstructured":"Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ: Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest. 2002, 122 (5): 1609-1614. 10.1378\/chest.122.5.1609.","journal-title":"Chest"},{"issue":"4","key":"4213_CR14","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1016\/j.ijid.2009.05.007","volume":"14","author":"J Li","year":"2010","unstructured":"Li J, Munsiff SS, Tarantino T, Dorsinville M: Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010, 14 (4): e292-e297. 10.1016\/j.ijid.2009.05.007.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"4213_CR15","first-page":"719","volume":"13","author":"A Machado","year":"2009","unstructured":"Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares M, Reis MG, Arruda S, Riley LW: Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis. 2009, 13 (6): 719-725.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"4213_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1164\/rccm.200510-1667OC","volume":"174","author":"FK Shieh","year":"2006","unstructured":"Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ: Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006, 174 (6): 717-721. 10.1164\/rccm.200510-1667OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4213_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10903-010-9393-x","volume":"14","author":"JA Zuniga","year":"2010","unstructured":"Zuniga JA: Medication adherence in hispanics to latent tuberculosis treatment: a literature review. J Immigr Minor Health. 2010, 14 (1): 23-9.","journal-title":"J Immigr Minor Health"},{"issue":"1","key":"4213_CR18","first-page":"14","volume":"69","author":"EL West","year":"2008","unstructured":"West EL, Gadkowski LB, Ostbye T, Piedrahita C, Stout JE: Tuberculosis knowledge, attitudes, and beliefs among North Carolinians at increased risk of infection. N C Med J. 2008, 69 (1): 14-20.","journal-title":"N C Med J"},{"issue":"5","key":"4213_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1086\/422995","volume":"39","author":"AS Gershon","year":"2004","unstructured":"Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J: Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis. 2004, 39 (5): 667-672. 10.1086\/422995.","journal-title":"Clin Infect Dis"},{"key":"4213_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/1471-2334-10-267","volume":"10","author":"A Diaz","year":"2010","unstructured":"Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, et al: Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis. 2010, 10: 267-10.1186\/1471-2334-10-267.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4213_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0975-7406.62698","volume":"2","author":"N Akhtar","year":"2010","unstructured":"Akhtar N, Khan BA, Mahmood T, Parveen R, Qayum M, Anwar M, Shahiq Uz Z, Farooq M: Formulation and evaluation of antisebum secretion effects of sea buckthorn w\/o emulsion. J Pharm Bioallied Sci. 2010, 2 (1): 13-17. 10.4103\/0975-7406.62698.","journal-title":"J Pharm Bioallied Sci"},{"issue":"2","key":"4213_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0749-3797(00)00283-X","volume":"20","author":"CK Malotte","year":"2001","unstructured":"Malotte CK, Hollingshead JR, Larro M: Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med. 2001, 20 (2): 103-107. 10.1016\/S0749-3797(00)00283-X.","journal-title":"Am J Prev Med"},{"issue":"6","key":"4213_CR23","first-page":"576","volume":"1","author":"BT Mangura","year":"1997","unstructured":"Mangura BT, Passannante MR, Reichman LB: An incentive in tuberculosis preventive therapy for an inner city population. Int J Tuberc Lung Dis. 1997, 1 (6): 576-578.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4213_CR24","first-page":"CD003343","volume":"4","author":"J Volmink","year":"2007","unstructured":"Volmink J, Garner P: Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2007, 4: CD003343-","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-12-468\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-12-468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T23:27:38Z","timestamp":1468366058000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-12-468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,21]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-12-468","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,21]]},"article-number":"468"}}